Epé

The stem bark hydroethanolic extract (HEVe) of Virola elongata contains tryptamine alkaloids, bis-tetrahydrofuran lignans (yangambin, sesartemin), phenolic acids, neolignans, and flavonoids that suppress pro-inflammatory cytokines, modulate CNS activity, and protect gastric mucosa. In LPS-stimulated macrophage models, HEVe reduced nitric oxide production by 54.8–71.0% at 1–20 μg/mL and lowered IL-1β by 42.0–49.7%, while in vivo mouse models demonstrated reduced peritoneal leukocyte infiltration and elevated anti-inflammatory IL-10.

Origin & History

Virola elongata is a canopy tree in the Myristicaceae (nutmeg) family native to the Amazon basin, with its range spanning Brazil, Ecuador, Venezuela, Peru, and Colombia. It thrives in humid lowland tropical rainforests, often along river margins and flooded várzea forest systems, growing at elevations below 500 m. The tree is not commercially cultivated; all documented material derives from wild harvest of stem bark by indigenous communities, particularly the Yanomami of Brazil and Venezuela and various Ecuadorian Amazonian groups.

Historical & Cultural Context

Virola species have been central to the spiritual and medicinal practices of multiple Amazonian indigenous groups for centuries; Virola elongata specifically is employed by Yanomami shamans (hekura practitioners) in Venezuela and Brazil, where the bark resin is processed into the hallucinogenic snuff known as 'Epé' or 'Yäkoanä,' used to commune with spirits (hekura) and confer hunting magic and healing power. The Yanomami ritual involves experienced practitioners (shapori) insufflating large quantities of the snuff through long bamboo tubes, entering visionary states used for diagnosing illness and negotiating with supernatural entities—a practice documented in detail by ethnobotanist Richard Evans Schultes and anthropologist Napoleon Chagnon during the mid-20th century. In Ecuador, non-ritual use of stem bark decoctions for stomach ailments and inflammation represents a distinct ethnomedical tradition that does not necessarily involve psychoactive doses and is practiced by communities along the Napo and Pastaza river systems. The pharmacological investigation of Virola elongata emerged from these ethnobotanical records, with chemical and biological studies in the 21st century providing molecular validation for both the digestive and psychoactive traditional applications.

Health Benefits

- **Anti-inflammatory Activity**: HEVe suppresses nitric oxide, TNF-α, and IL-1β production in LPS-stimulated RAW 264.7 macrophages and reduces peritoneal leukocyte and neutrophil counts in murine peritonitis models, with NO reduced by up to 71.0% at 20 μg/mL.
- **Gastroprotective Effects**: Oral administration of HEVe in rodent ulcer models increases gastric mucus secretion and exerts antioxidant protection of the gastric mucosa, consistent with its traditional use by Ecuadorian and Brazilian communities for stomach pain, indigestion, and ulcers.
- **Antioxidant Properties**: Phenolic acids, resveratrol, quinic acid, flavonoids, and monomeric catechins identified via UHPLC-MS contribute to free radical scavenging activity, protecting cells from oxidative stress-induced damage.
- **CNS Modulation via Lignans**: Bis-tetrahydrofuran lignans—particularly yangambin and epi-yangambin—reduce spontaneous locomotor activity and isolation-induced aggression in mice, suggesting anxiolytic or sedative potential mediated through central nervous system pathways.
- **Psychoactive and Entheogenic Properties**: High concentrations of tryptamine alkaloids in the bark resin produce profound hallucinogenic effects through serotonin receptor agonism, a mechanism pharmacologically analogous to N,N-dimethyltryptamine (DMT) found in related Virola species.
- **Topical Anti-edema Effects**: HEVe formulated as a topical gel demonstrated significant reduction in croton oil-induced ear edema in mice, suggesting transdermal bioavailability of anti-inflammatory lignans and phenolics relevant to local inflammatory conditions.
- **Immunomodulatory Effects**: In vivo LPS-peritonitis mouse models showed HEVe elevated IL-10 (a key anti-inflammatory cytokine) while simultaneously increasing IL-13, indicating bidirectional immune regulation beyond simple cytokine suppression.

How It Works

HEVe exerts anti-inflammatory effects primarily by suppressing NF-κB-dependent transcription of pro-inflammatory mediators in activated macrophages: it reduces nitric oxide synthesis (likely via iNOS downregulation), inhibits TNF-α release by 5.3–7.0%, and suppresses IL-1β secretion by 42.0–49.7% at 1–20 μg/mL, while upregulating IL-13 (27.7–32.9%) and IL-10, shifting the immune response toward an anti-inflammatory phenotype. Bis-tetrahydrofuran lignans (yangambin, epi-yangambin, sesartemin, epi-sesartemin) are responsible for behavioral CNS effects, likely through modulation of monoaminergic or GABAergic neurotransmission, reducing locomotor activity and aggression in animal models independent of the alkaloid fraction. Tryptamine alkaloids in the bark resin act as agonists at 5-HT2A serotonin receptors, producing hallucinogenic effects mechanistically comparable to DMT, with potency dependent on alkaloid concentration and route of administration. Gastroprotection arises from antioxidant phenolics (resveratrol, quinic acid, catechins) scavenging reactive oxygen species at the gastric mucosa and from stimulus-driven increases in protective mucus secretion.

Scientific Research

All available evidence for Virola elongata is preclinical, derived from in vitro cell culture experiments and in vivo murine models; no human clinical trials have been conducted or registered in publicly searchable databases as of 2024. Anti-inflammatory data originate from LPS-stimulated RAW 264.7 macrophage assays and LPS-induced peritonitis mouse models, with cytotoxicity profiled across 24–72 hours (IC50 161.94–302.58 μg/mL), establishing a preliminary safety window for in vitro concentrations. Gastroprotective and topical anti-edema studies used standard murine protocols (ethanol-induced ulcer models and croton oil ear edema assays), but exact animal group sizes, statistical power, and effect magnitudes beyond directional trends are not fully reported in available literature. Ethnopharmacological literature and alkaloid characterization studies provide chemical contextualization for the psychoactive uses, but pharmacokinetic, bioavailability, and human dose-response data are entirely absent, rendering the overall evidence base preliminary.

Clinical Summary

No clinical trials in humans have been performed on Virola elongata or its extracts; the entirety of the evidence base is composed of in vitro macrophage assays, murine inflammation and ulcer models, and ethnopilotstudy chemical fractionation reports. The most quantitatively detailed outcomes are from RAW 264.7 macrophage studies showing dose-dependent NO reduction (54.8–71.0% at 1–20 μg/mL) and IL-1β suppression (42.0–49.7%), and from cytotoxicity assays establishing IC50 values of 161.94–302.58 μg/mL across 24–72 hours. In vivo murine peritonitis and ear edema models directionally confirm anti-inflammatory activity but lack detailed reporting of group sizes, confidence intervals, and standardized effect sizes, limiting interpretability. Confidence in translating these findings to human clinical utility is very low; preclinical signals are hypothesis-generating only and require pharmacokinetic studies and human safety trials before any therapeutic claims can be substantiated.

Nutritional Profile

Virola elongata bark is not consumed as a food source and has no established macronutrient or micronutrient profile in nutritional databases. Phytochemically, UHPLC-MS analysis of HEVe identifies quinic acid (a cyclitol acid with antioxidant and prebiotic properties), resveratrol (a stilbenoid polyphenol), phenolic acids (unspecified subtypes), neolignans, flavonoids, and monomeric catechins as the principal non-alkaloid constituents; absolute concentrations in plant material have not been quantified in published studies. The non-alkaloidal lignan fraction—comprising sesartemin, epi-sesartemin, yangambin, and epi-yangambin as bis-tetrahydrofuran lignans—is responsible for CNS behavioral effects; the alkaloid fraction contains tryptamines (structurally analogous to DMT) present in pharmacologically significant concentrations only in the concentrated resin used for snuff preparation. Bioavailability of any constituent has not been characterized in pharmacokinetic studies; traditional preparation methods (aqueous and hydroethanolic maceration) suggest reasonable extraction of polar phenolics and moderate extraction of lignans, while tryptamines require higher-polarity solvents or concentrated resin processing.

Preparation & Dosage

- **Hydroethanolic Extract (HEVe)**: Prepared by maceration of inner stem bark in ethanol/water solvent systems; used exclusively in experimental research at concentrations of 1–400 μg/mL in vitro and unspecified oral doses in rodent models; no human-standardized dose exists.
- **Traditional Oral Decoction**: Indigenous preparation involves boiling or cold-water maceration of inner stem bark; used by Ecuadorian and Brazilian Amazonian communities for gastric complaints and inflammation at culturally determined volumes.
- **Psychoactive Snuff (Epé)**: The Yanomami prepare hallucinogenic snuff by drying, pulverizing, and concentrating resinous bark material, often mixed with ash from Elizabetha princeps; insufflated directly into nasal passages during ritual contexts—no safe supplemental dose is established for this form.
- **Petroleum Ether Alkaloid Extract**: Used in research fractionation to isolate tryptamine alkaloids with high efficiency; not suitable for human use as a supplement form.
- **Topical Gel**: Experimental HEVe gel formulations tested in murine ear edema models; no standardized concentration or application frequency has been validated for human use.
- **Standardization**: No commercial standardization percentages for any specific compound class (lignans, alkaloids, phenolics) have been established or published.

Synergy & Pairings

No formal synergistic combination studies have been conducted for Virola elongata extracts with other ingredients; traditional Yanomami snuff preparation combines Epé resin with ash from Elizabetha princeps (a leguminous tree), which likely functions as an alkalizing agent to enhance transmucosal absorption of free-base tryptamine alkaloids across nasal membranes, a mechanism well-documented in analogous ayahuasca and snuff traditions. The phenolic antioxidant fraction (resveratrol, catechins, quinic acid) of HEVe may theoretically exhibit additive anti-inflammatory synergy with other NF-κB inhibitors such as curcumin or quercetin, based on shared pathway modulation, though no co-administration studies exist for this species. Given the lignan content's apparent GABAergic or monoaminergic CNS modulation, combining non-psychoactive HEVe fractions with other adaptogenic herbs targeting the HPA axis represents a speculative but unexplored research direction.

Safety & Interactions

In vitro cytotoxicity data from RAW 264.7 macrophage assays indicate HEVe is non-toxic at concentrations up to 400 μg/mL tested and yields IC50 values of 161.94–302.58 μg/mL over 24–72 hours, establishing a preliminary in vitro safety threshold; however, no human safety data, maximum tolerated dose, or NOAEL from animal toxicology studies are reported in available literature. Tryptamine alkaloids at doses present in ritual snuff preparations carry significant psychoactive risks including perceptual distortion, tachycardia, hypertension, hyperthermia, and psychological distress; their use in combination with monoamine oxidase inhibitors (MAOIs) could potentiate serotonergic effects to dangerous levels, creating serotonin toxicity risk analogous to that documented for other tryptamine-containing plants. Lignans with CNS depressant properties (yangambin series) may additively or synergistically enhance sedation when combined with benzodiazepines, barbiturates, opioids, or alcohol, based on animal behavioral data; this interaction has not been characterized in humans. Virola elongata preparations of any type should be avoided during pregnancy and lactation due to the complete absence of safety data and the theoretical teratogenic and neurotoxic risk posed by tryptamine alkaloids and CNS-active lignans; individuals with psychiatric disorders, cardiovascular disease, or those taking serotonergic medications should not use any preparation of this plant.